国产成人嫩模一区二区|超级黄色网页|兔子先生tz|麻豆文化传媒网站官网污|在线播放欧美日韩精品|爱豆影视传媒免费下载|蜜桃影像传媒av剧情|麻豆文化传媒APP最新iOS|陈可心倩女幽魂爱豆传媒|91国视频产,国产传媒播放,想看三级片,网红吃瓜黑料爆料网反差

 
師資隊(duì)伍
余健秀
  作者:  2023-03-01

基本信息 >>>

                                                                       

  余健秀

  蛋白質(zhì)修飾,、RNA修飾與腫瘤研究組

  電話:021-54660870
  郵箱: [email protected]
du.cn

研究方向>>>

1.蛋白質(zhì)修飾調(diào)控腫瘤發(fā)生發(fā)展

2.蛋白質(zhì)修飾調(diào)控miRNA的生物合成與作用效率

3RNA降解機(jī)制

4.蛋白質(zhì)修飾調(diào)控RNA修飾及其功能

個人簡歷 >>>

余健秀, 男,,博士,,現(xiàn)任上海交通大學(xué)醫(yī)學(xué)院PI,、特聘教授、博士生導(dǎo)師,、生物化學(xué)與分子細(xì)胞學(xué)系科研副主任,。

1990年-華南農(nóng)業(yè)大學(xué)學(xué)士

1996年-中山大學(xué)理學(xué)碩士

2000年-中山大學(xué)理學(xué)博士

2000-2002中山大學(xué)生命科學(xué)學(xué)院副教授

2002-2007年美國Sanford-Burnham Medical Research Institute/UCSD博士后

2007-2008年美國Sanford-Burnham Medical Research Institute/UCSD, Staff Scientist

2008-2009年美國紐約大學(xué)Langone Medical Center研究助理教授

2009-至今上海交通大學(xué)醫(yī)學(xué)院PI、研究員

2016-至今上海交通大學(xué)醫(yī)學(xué)院聘教授

2018-至今生物化學(xué)與分子細(xì)胞學(xué)系科研副主任

2018-至今擔(dān)任中國抗癌協(xié)會腫瘤標(biāo)志專業(yè)委員會“非編碼與腫瘤研究”專家委員會副組長

2018-至今中國細(xì)胞生物學(xué)醫(yī)學(xué)細(xì)胞生物學(xué)分會常委

科研項(xiàng)目 >>>

1. 國家自然科學(xué)基金重點(diǎn)項(xiàng)目,, AT2細(xì)胞Fbxo45缺失影響組蛋白水平和染色質(zhì)穩(wěn)定性導(dǎo)致肺腺癌發(fā)生,,#82230100261萬元,,主持人, 2023.01~2027.12,。

2. 國家自然科學(xué)基金-國際(地區(qū))合作與交流項(xiàng)目-組織間合作研究 NSFC-FDCT(內(nèi)地-澳門)SLBP 類泛素化在非小細(xì)胞肺癌中的功能調(diào)控機(jī)制及干預(yù)策略研究,,#32461160262,,170萬元,主持人, 2025.01~2027.12,。

3. 國家自然科學(xué)基金面上項(xiàng)目,,應(yīng)激壓力下PABPC1類泛素化調(diào)控應(yīng)激顆粒形成及基因表達(dá),#32271310,,54萬元,,主持人,2023.01~2026.12,。

4. 國家重點(diǎn)研發(fā)計(jì)劃政府間國際科技創(chuàng)新合作項(xiàng)目,,惡性腫瘤發(fā)生發(fā)展中關(guān)鍵表觀遺傳與轉(zhuǎn)錄調(diào)控因子的蛋白質(zhì)修飾及其功能,#2019YFE0110600,,179萬元,,首席主持人(科學(xué)家),2020.12~2023.11,。

5. 國家自然基金創(chuàng)新研究群體項(xiàng)目, 應(yīng)激與腫瘤,,#81721004, 1050萬元,第一核心骨干,,2018/01-2023/12,。

6. 國家自然科學(xué)基金重點(diǎn)項(xiàng)目,PTENDNA損傷修復(fù)中介導(dǎo)組蛋白H2A/H3修飾調(diào)控前列腺癌發(fā)生發(fā)展,, #81630075,,275萬元,,主持人,2017.01~2021.12,。

7. 國家自然科學(xué)基金面上項(xiàng)目,,Ago2乙酰化在miRNA途徑中的功能與機(jī)制,,#31671345,,65萬元,主持人,,2017.01~2020.12,。

8. 國家自然基金面上項(xiàng)目,Shp2類泛素(SUMO)化修飾促進(jìn)ERK信號通路激活而加速肝癌發(fā)生發(fā)展,,# 81472571,,主持人,2015/01-2018/12,。

9. 科技部973/重大科學(xué)研究計(jì)劃課題,,惡性腫瘤免疫負(fù)調(diào)控分子網(wǎng)絡(luò)的形成與干預(yù)--腫瘤細(xì)胞與免疫細(xì)胞膜蛋白分子間的相互作用,#2012CB917101,,子課題主持人,,2012.01~2016.12

10. 科技部973/重大科學(xué)研究計(jì)劃課題,,人類微RNA的調(diào)控機(jī)制及在細(xì)胞功能與命運(yùn)決定中的作用--RNA結(jié)合蛋白的修飾與功能,,#2011CB811303,子課題主持人,,2011.01~2015.12,。

論文與專著 >>>


1. Yang Q#, Zhou Z#, Li L#, Lu R#, Hou G#, Huang C, Huang J, Li H, Zhang Y, Li J, Zhang Y, Xu A, Chen R, Wang Y, Zhao X, Huang J, Wang Y*, Zhao X*, Yu J*.The NEXT complex regulates H3K27me3 levels to affect cancer progression by degrading G4/U-rich lncRNAs. Nucleic Acids Res. 2025 Feb 8;53(4):gkaf107. doi: 10.1093/nar/gkaf107.

2. Li L#, Li J#, Chen R#, Huang C#, Zuo Y#, Lu R, Liu X, Huang J, Wang Y, Zhao X, Cheng J, Zhao X*, Du C*, Yu J*. Loss of Fbxo45 in AT2 cells leads to insufficient histone supply and initiates lung adenocarcinoma. Cell Death Differ. 2024 Dec 13. doi: 10.1038/s41418-024-01433-z.

3. Zhao X*, Cao Y, Lu R, Zhou Z, Huang C, Li L, Huang J, Chen R, Wang Y, Huang J, Cheng J, Zheng J, Fu Y*, Yu J*. Phosphorylation of AGO2 by TBK1 Promotes the Formation of Oncogenic miRISC in NSCLC. Adv Sci (Weinh). 2024 Apr;11(15):e2305541.

4. Fang J, Zhang Y, Huang C, Lu R, Yu J, Chen R, Wang Y, Zhao X, Yu J*, Huang J*. Glucose-mediated N-glycosylation of RPTPα affects its subcellular localization and Src activation. Oncogene. 2023 Feb 10. doi: 10.1038/s41388-023-02622-9. Online ahead of print. PMID: 36765146.

5. Guo Y#, He J#, Zhang H#, Chen R#, Li L, Liu X, Huang C, Qiang Z, Zhou Z, Wang Y, Huang J, Zhao X, Zheng J, Chen GQ, Yu J*. Linear ubiquitination of PTEN impairs its function to promote prostate cancer progression. Oncogene. 2022 Oct;41(44):4877-4892.

6. Zhang H#, Zhao X#, Guo Y#, Chen R, He J, Li L, Qiang Z, Yang Q, Liu X, Huang C, Lu R, Fang J, Cao Y, Huang J, Wang Y, Huang J, Chen GQ*, Cheng J*, Yu J*. Hypoxia regulates overall mRNA homeostasis by inducing Met1-linked linear ubiquitination of AGO2 in cancer cells. Nat Commun. 2021 Sep 13;12(1):5416.

7. Hou G#, Zhao X#, Li L, Yang Q, Liu X, Huang C, Lu R, Chen R, Wang Y, Jiang B*, Yu J*. SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs. Nucleic Acids Res. 2021 Mar 18;49(5):2859-2877.

8. Zhang H, Zhao X, Guo Y, Chen R, He J, Li L, Qiang Z, Yang Q, Liu X, Huang C, Lu R, Fang J, Cao Y, Huang J, Wang Y, Huang J, Chen GQ*, Cheng J*, Yu J*. Hypoxia regulates overall mRNA homeostasis by inducing Met1-linked linear ubiquitination of AGO2 in cancer cells. Nat Commun. 2021 Sep 13;12(1):5416.

9. Wang Y, Yu Y, Pang Y, Yu H, Zhang W, Zhao X, Yu J*. The distinct roles of zinc finger CCHC-type (ZCCHC) superfamily proteins in the regulation of RNA metabolism. RNA Biol. 2021 Dec;18(12):2107-2126.

10. Wang Y, Yu J*. Dissecting multiple roles of SUMOylation in prostate cancer. Cancer Lett. 2021 Aug 28;521:88-97.

11. Hou G, Zhao X, Li L, Yang Q, Liu X, Huang C, Lu R, Chen R, Wang Y, Jiang B*, Yu J*. SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs. Nucleic Acids Res. 2021 Mar 18;49(5):2859-2877.

12. Deng R, Guo Y, Li L, He J, Qiang Z, Zhang H, Chen R, Wang Y, Zhao X*, Yu J*. BAP1 suppresses prostate cancer progression by deubiquitinating and stabilizing PTEN.  Mol Oncol. 2021 Jan;15(1):279-298.

13. Zhao X, Wang Y, He J, Deng R, Huang X, Guo Y, Li L, Xie R*, Yu J*. LncRNA UCA1 maintains the low-tumorigenic and nonmetastatic status by stabilizing E-cadherin in primary prostate cancer cells. Mol Carcinog. 2020 Oct;59(10):1174-1187.

14. Dou J, Zhang H, Chen R, Shu Z, Yuan H, Zhao X, Wang Y, Huang J, Zhou A*, Yu J*. SUMOylation modulates the LIN28A-let-7 signaling pathway in response to cellular stresses in cancer cells. Mol Oncol. 2020 Sep;14(9):2288-2312.

15. Lin R, Zhan M, Yang L, Wang H, Shen H, Huang S, Huang X, Xu S, Zhang Z, Li W, Liu Q, Shi Y, Chen W, Yu J*, Wang J*. Deoxycholic acid modulates the progression of gallbladder cancer through N6-methyladenosine-dependent microRNA maturation. Oncogene. 2020 Jun; 39(26):4983-5000.

16. Liu T, Zhang H, Fang J, Yang Z, Chen R, Wang Y, Zhao X, Ge S, Yu J*, Huang J*. AGO2 phosphorylation by c-Src kinase promotes tumorigenesis. Neoplasia. 2020 Mar;22(3):129-141.

17. Cui N, Liu T, Guo Y, Dou J, Yang Q, Zhang H, Chen R, Wang Y, Zhao X, Yu J*, Huang J*. SUMOylation of Csk Negatively Modulates its Tumor Suppressor Function. Neoplasia. 2019 May 21; 21(7):676-688.

18. Zhang H, Wang Y, Dou J, Guo Y, He J, Li L, Liu X, Chen R, Deng R, Huang J, Xie R, Zhao X*, Yu J*. Acetylation of AGO2 promotes cancer progression by increasing oncogenic miR-19b biogenesis. Oncogene. 2019 Feb; 38(9):1410-1431.

19. Du Y, Hou G, Zhang H, Dou J, He J, Guo Y, Li L, Chen R, Wang Y, Deng R, Huang J, Jiang B, Xu M, Cheng J, Chen GQ, Zhao X*, Yu J*.SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function. Nucleic Acids Res. 2018, 46(10) 5195-5208.

20. Yuan H, Deng R, Zhao X, Chen R, Hou G, Zhang H, Wang Y, Xu M, Jiang B*, Yu J*. SUMO1 modification of KHSRP regulates tumorigenesis by preventing the TL-G-Rich miRNA biogenesis. Mol Cancer. 2017 Oct 11; 16(1):157.

21. Wang J, Deng R, Cui N, Zhang H, Liu T, Dou J, Zhao X, Chen R, Wang Y, Yu J*, Huang J*. Src SUMOylation Inhibits Tumor Growth Via Decreasing FAK Y925 Phosphorylation. Neoplasia. 2017 Oct 22; 19(12):961-971.

22. Jiang H, Deng R, Yang X, Shang J, Lu S, Zhao Y, Song K, Liu X, Zhang Q, Chen Y, Chinn YE, Wu G, Li J, Chen G, Yu J*, Zhang J*. Peptidomimetic inhibitors of APC-Asef interaction block colorectal cancer migration.Nature Chem Biol. 2017, 13(9):994-1001.

23. Zhao X, Deng R, Wang Y, Zhang H, Dou J, Li L, Du Y, Chen R, Cheng J, Yu J*. Twist1/Dnmt3a and miR186 establish a regulatory circuit that controls inflammation-associated prostate cancer progression. Oncogenesis. 2017, 6(4): e315.

24. Zhu C, Chen C, Chen R, Deng R, Zhao X, Zhang H, Duo J, Chen Q, Jin H, Wang Y, Huang J, Xu M*, Yu J*. K259-SUMOylation of DGCR8 promoted by p14ARF exerts a tumor-suppressive function. J Mol Cell Biol. 2016 Oct 07, 8(5):456-458.

25. Chen C, Zhu C, Huang J, Zhao X, Deng R, Zhang H, Dou J, Chen Q, Xu M, Yuan H, Wang Y, Yu J*. SUMOylation of TARBP2 regulates miRNA/siRNA efficiency.Nature Communications. 2015, 6:8899.

26. Lu S, Deng R, Jiang H, Song H, Li S, Shen Q, Huang W, Nussinov R, Yu J*, Zhang J*. The Mechanism of ATP-Dependent Allosteric Protection of Akt Kinase Phosphorylation.Structure. 2015, 23(9):1725-34.

27. Zhu C, Chen C, Huang J, Zhang H, Zhao X, Deng R, Dou J, Jin H, Chen R, Xu M, Chen Q, Wang Y, Yu J*. SUMOylation at K707 of DGCR8 controls direct function of primary microRNA.Nucleic Acids Res. 2015, 43(16):7945-60.

28. Chen Q, Zhao X, Zhang H, Yuan H, Zhu M, Sun Q, Lai X, Wang Y, Huang J, Yan J, Yu J*. MiR-130b suppresses prostate cancer metastasis through down-regulation of MMP2. Mol Carcinogen. 2015, 54(11):1292-300.

29. Lai  X, Chen Q, Zhu C, Deng R, Zhao X, Chen C, Wang Y, Yu J*, Huang J*. Regulation of RPTPα-c-Src signalling pathway by miR-218.FEBS J. 2015, 282(14):2722-34.

30. Sun Q, Zhao X, Liu X, Wang Y, Huang J, Jiang B, Chen Q*, Yu J*. miR-146a functions as a tumor suppressor in prostate cancer by targeting Rac1.Prostate. 2014, 74(16):1613-21.

31. Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng R, Wang Y, Huang J, Xu M, Yan J, Yu J*. lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI.FEBS J. 2014, 281:3766-3775.

32. Qu Y, Chen Q, Lai X, Zhu C, Chen C, Zhao X, Deng R, Xu M, Yuan H, Wang Y, Yu J*, Huang J*. SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1.Mol Cancer, 2014, 13(1):95.

33. Liu X, Chen Q, Yan J, Wang Y, Zhu C, Chen C, Zhao X, Xu M, Sun Q, Deng R, Zhang H, Qu Y, Huang J, Jiang B, Yu J*. MiRNA-296-3p-ICAM-1 axis promotes metastasis of prostate cancer by possible enhancing survival of natural killer cell-resistant circulating tumour cells. Cell Death Dis. 2013, 4:e928.

34. Yu J*, Deng R, Zhu HH, Zhang SS, Zhu C, Montminy M, Davis R, Feng GS*. Modulation of fatty acid synthase degradation by concerted action of p38 MAP kinase, E3 ligase COP1 and SH2-tyrosine phosphatase Shp2. J Biol Chem. 2013, 288(6):3823-30.

35. Huang J, Yan J, Zhang J, Zhu S, Wang Y, Shi T, Zhu C, Chen C, Liu X, Cheng J, Mustelin T, Feng GS, Chen G, Yu J*. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane.Nature Communications. 2012, 3:911.

36. Liu X, Wang Y, Sun Q, Yan J, Huang J, Zhu S, Yu J*. Identification of microRNA transcriptome involved in human natural killer cell activation. Immunol Lett. 2012, 143(2):208-17.

37. Yu J*, Zhang SS, Saito K, Williams S, Arimura Y, Ma Y, Ke Y, Baron V, Mercola D, Feng GS, Adamson E*, Mustelin T. PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J. 2009, 28(1):21-33.

38. Yu J, Baron V, Mercola D, Mustelin T, Adamson ED*. A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Cell Death and Differentiation. 2007, 14(3):436-46.

39.  Yu J, de Belle I, Liang H, Adamson ED*. Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses. Molecular Cell, 2004, 15(1): 83-94.